Síndrome neuroléptica maligna: relato de caso com recorrência associada ao uso de olanzapina
| Autor: | Martina Kranich, Marcos C. Sandmann, De Bittencourt Pr, Ricardo A. Hanel |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Tachycardia
Olanzapine Neurosciences. Biological psychiatry. Neuropsychiatry olanzapina haloperidol bromocriptina medicine Haloperidol síndrome neuroléptica maligna Leukocytosis Chlorpromazine biology business.industry medicine.disease Neuroleptic malignant syndrome Neurology Dopamine receptor Anesthesia biology.protein Creatine kinase clorpromazina Neurology (clinical) medicine.symptom dantrolene business RC321-571 medicine.drug |
| Zdroj: | Arquivos de Neuro-Psiquiatria, Vol 56, Iss 4, Pp 833-837 (1998) |
| ISSN: | 0004-282X |
| DOI: | 10.1590/s0004-282x1998000500022 |
| Popis: | The neuroleptic malignant syndrome (NMS) consists in an idiosyncratic reaction to neuroleptic drugs, probably related to a blockage of dopamine receptors in basal ganglia. Research criteria for diagnosing NMS from DSM-IV require severe rigidity and fever accompanied by 2 of 10 minor features including diaphoresis, dysphagia, tremor, incontinence, altered mentation, mutism, tachycardia, elevated or labile blood pressure, leukocytosis and elevation of creatine phosphokinase. From a clinical point of view, the NMS may range a large spectrum of presentations. Haloperidol is the most frequent drug associated with this syndrome. We report the case of a 30 year-old man who developed NMS at two different occasions, the first related to haloperidol and chlorpromazine and the second related to olanzapine, to our knowledge without previous mention in the indexed literature. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|